附桂骨痛胶囊联合来氟米特治疗类风湿关节炎的临床研究

目的探讨附桂骨痛胶囊联合来氟米特治疗类风湿关节炎的临床疗效。方法选取2017年8月—2019年12月上海交通大学医学院附属第九人民医院北部90例类风湿关节炎患者作为研究对象,按照治疗方法分为对照组和观察组,每组各45例。对照组口服来氟米特片,10 mg/次,1次/d。观察组在对照组治疗的基础上口服附桂骨痛胶囊,4粒/次,3次/d。两组连续治疗3个月。对比两组的临床总有效率,比较两组关节肿胀数、压痛数、晨僵时间的变化。检测患者治疗前后血清C反应蛋白(CRP)、白细胞介素-32(IL-32)、类风湿因子(RF)、血沉的水平及血液流变学指标。记录药物不良反应的发生情况。结果治疗后,观察组患者总有效率为95.56%,对照组为82.22%,两组间比较差异有统计学意义(P<0.05)。治疗后,两组关节肿胀数、压痛数、晨僵时间显著降低(P<0.05),以观察组降低更明显(P<0.05)。治疗后,两组的CRP、IL-32、RF、血沉水平均显著降低(P<0.05);治疗后,观察组的CRP、IL-32、RF、血沉水平显著低于对照组,差异有统计学意义(P<0.05)。治疗后,两组的全血黏度、血浆比黏度、红细胞压积、血小板聚集率均显著降低(P<0.05);治疗后,观察组的全血黏度、血浆比黏度、红细胞压积、血小板聚集率显著低于对照组,差异有统计学意义(P<0.05)。两组药物不良反应的发生率无明显差异。结论附桂骨痛胶囊联合来氟米特片治疗类风湿关节炎的疗效确切,可降低炎症反应,改善血液流变学水平,显著改善临床症状。

Biocompatibility of bio-Mg-Zn alloy within bone with heart, liver, kidney and spleen

A magnesium-zinc alloy rod was implanted into the marrow cavity of the distal femur in New Zealand rabbits. The femur with the implanted alloy was compared with the contralateral femur in which a bone tunnel without implant was formed as a control. Degradation of the magnesium-zinc alloy was analyzed via X-ray, scanning electron microscopy, and element energy spectrum analysis. Serum magnesium, liver and kidney function tests, and myocardial enzymes were measured. Heart, liver, kidney and spleen were sectioned for pathological analysis, and the effects of the implanted material on the histology and function of important organs were analyzed. Magnesium-zinc alloy was resorbed from the bone marrow cavity of the femur; 87% of the alloy was degraded within 14 weeks after the surgery. There were no significant differences in serum magnesium, liver or kidney function tests, or myocardial enzymes be- fore the surgery and after degradation of the magnesium-zinc alloy. Histology of the heart, liver, kidney, and spleen did not change. This study demonstrated that magnesium-zinc alloy can be resorbed in bone, and that the degradation products have good biocompatibility with heart, liver, kidney, and spleen.